0K4.F - Akero Therapeutics, Inc.
| Previous Close | 41.80 |
| Open | 41.00 |
| Bid | 41.00 x N/A |
| Ask | 41.40 x N/A |
| Day's Range | 41.00 - 41.00 |
| 52 Week Range | 7.40 - 53.50 |
| Volume | |
| Avg. Volume | 4 |
| Market Cap | 2.276B |
| Beta (5Y Monthly) | -0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the
- GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 -- -- SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of this year -- -- Results from the Phase 2b SYMMETRY study, evaluating treatment of patients with compensated cirrhosis due to NASH, on track to be reported in the fourth quarter of this year – -- After close of
- GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Synchrony Histology Synchrony Histology Trial Logo Synchrony Outcomes Synchrony Outcomes Trial Logo Synchrony Real-World Synchrony Real-World Trial Logo The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY Real-World are expected to begin enrollment in the second half of this year Consistent with the encouraging clini
- GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022. “The wins we celebrated in 2022 further solidify our confidence in efruxifermin (EFX) as a potential best-in-class FGF21 analog addressing all core
- GlobeNewswire
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. “Akero is thrilled to welcome Patrick to the team, especially following last year’s HARMONY study results, which further demonstrate EFX’s potential to treat
- GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. A live webcast of the Company presentation will be available through the investor r
- GlobeNewswire
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023 Results of the cohort D expansion to evaluate EFX in combination with GLP-1 therapy in patients with pre-cirrhotic NASH expected in second quarter of 2023 Following designation of EFX as a Breakthrough Therapy, a meeting has been scheduled for March 2023 with FDA to review results of the Phase 2b HARMONY study and to obtain feedback on a proposed Phase 3 clinical program SOUTH SAN
- GlobeNewswire
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeksSOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that efruxifermin (EFX) has received a Breakth
- GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month: Jefferies London Healthcare Conference: Fireside chat on Thursday, November 17 at 8:00 a.m. GMT (3:00 a.m. ET) in London, England.EvercoreISI HealthCONx Conf
- GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD categorySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, announced it will present late-breaking oral and poster presentations on its lead product candidate efruxifermin (EFX) today at the Am
- GlobeNewswire
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2022 and provided business updates. "Our recently reported Week 24 results from the Phase 2b HARMONY study in patients with pre-cirrhotic NASH (F2-F3) contribute to the
- GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T. A webcast of the Company presentation will be available through the investor relations secti
- GlobeNewswire
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option
- GlobeNewswire
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero
- GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $175.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to grant
- GlobeNewswire
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) 50mg (41%) and 28mg (29%) groups demonstrated fibrosis improvement AND resolution of NASH, six to eight times the placebo rate (5%) EFX-treated patients also experienced statistically significant improvements in liver fat, liver
- GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical dataSOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evalu
- GlobeNewswire
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3), patients with cirrhosis also had improved markers of liver injury, glucose metabolism, and lipid metabolism SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious m
- GlobeNewswire
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2022 and provided business updates. “During the second quarter of this year we took important steps toward optimizing our capital structure to support the ongoing developmen
- GlobeNewswire
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASHSOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation of an analysis from its Phase 2a BALANCED study of efruxifermin (EFX) in patients with biopsy-confirme
- GlobeNewswire
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing
- GlobeNewswire
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
Presentations to highlight the association of EFX’s antifibrotic effects as scored by histology with consistent reductions in biomarkers of liver collagen synthesisSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it will present oral and poster presentations at the Keystone Sympo
- GlobeNewswire
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's
